News und Analysen
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Poxel Announces Cash Runway Extended Through Q2 2025 Based upon Debt Restructuring Agreement and New Equity-linked Financing Facility
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic
Poxel Reports Financial Results for Full Year 2022 and Provides Corporate Update
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic
Cosmo reports record 2022 financial results exceeding guidance, increased dividend by 10%, confirms 2023 guidance
Inogen Announces Appointment of Tom West to Board of Directors and Retirement of Board Member Kristen Miranda
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Tom West to Inogen’s Board of
Poxel will Report its 2022 Full Year Results on March 23, 2023
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic
David A. Jones Elected Chairman of the Humana Foundation Board of Directors
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 41 years, today announced that David A. Jones Jr. has been elected to serve as Chairman of the Board of Directors
LivaNova to Announce First-Quarter 2023 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first-quarter 2023 results on Wednesday, May 3, 2023 at 1 p.m
Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 Open-Label Study in Adults with Social Anxiety Disorder
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous
EQS-News: Sernova: Abstract on First Cohort of its Phase 1/2 Study Involving Islet Transplantation into Cell Pouch Selected for Oral Podium Presentation at American Diabetes Association 83rd Scientific Sessions
Convatec Group PLC: Annual Report and Accounts 2022 and Notice of AGM
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Poxel to Report its 2022 Full Year Results by the End of March 2023
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic
Cosmo Pharmaceuticals announces that Cosmo Intelligent Medical Devices – IMD Ltd, fully owned subsidiary of Cosmo Pharmaceuticals, and Medtronic to expand cooperation on GI Genius™
Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023
Simulations Plus Sets Date for Second Quarter Fiscal Year 2023 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report financial results for the second quarter of fiscal year 2023, the period ended February 28, 2023, after the close of the
Navidea Biopharmaceuticals Reports Fourth Quarter 2022 Financial Results
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 2, 2023. The purpose of
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Agilent Announced as Instrument Business Outlook 2022 Company of the Year
Agilent Technologies Inc. (NYSE: A) announced today that it has been selected as Instrument Business Outlook (IBO) 2022 Company of the Year. IBO highlighted Agilent's increased growth in revenues
Newron Reports Compelling Topline Results From All Patients in Study 014, Its Phase II Clinical Trial Evaluating Evenamide as Add-on Therapy for Treatment-resistant Schizophrenia
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting